Amgen Sees A Vibrant Biosimilars Market As Its Business Pushes Into Blockbuster Territory

 
• By Mandy Jackson

Biosimilar executives Leah Christl and Chad Pettit see reasons for optimism in the US market as new launches and sales begin to add up. Amgen’s portfolio is annualizing at $1bn as of the fourth quarter.

Silhouettes
Amgen sees momentum building in the US biosimilars market • Source: Shutterstock

More from Strategy

More from Business